Akhila Balasubramanian
YOU?
Author Swipe
View article: Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 3. Analysis of immune cell populations in all samples
View article: Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Purpose:Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non–small cell lung cancers. There is an unmet need to improve outcomes for patients with this condition. Oncolytic viruses re…
View article: Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias
View article: Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 5. Functional markers expressed in CD8+ T cells in gPFS patients
View article: Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 5. CAVATAK samples: time between biopsies and biopsy sites.
View article: Supplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 4. Analysis of immune cell populations in gPFS and loPFS samples.
View article: Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
View article: Supplementary Figure S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 1. Survival analysis.
View article: A systematic literature review of MTAP deletions in solid and hematologic Cancers
A systematic literature review of MTAP deletions in solid and hematologic Cancers Open
This is the first systematic review to summarize the literature on MTAP deletions or loss of expression across several solid and hematologic cancers. MTAP deletions and/or loss of expression occur in many cancer types, presenting a promisi…
View article: Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan
Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan Open
Objective To describe standard of care and inform the evolving unmet need among extensive stage small-cell lung cancer (ES-SCLC) patients in Japan since approval of first-line anti-PD-L1 therapies, we describe treatment patterns and overal…
View article: Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer Open
Background The landscape of small cell lung cancer (SCLC) has changed since the 2019 and 2020 approvals of anti-PD-L1 atezolizumab and durvalumab for first-line (1L) treatment in combination with chemotherapy. We studied treatment patterns…
View article: Development of an algorithm to identify small cell lung cancer patients in claims databases
Development of an algorithm to identify small cell lung cancer patients in claims databases Open
Introduction The treatment landscape of small cell lung cancer (SCLC) is evolving. Evidence generated from administrative claims is needed to characterize real-world SCLC patients. However, the current ICD-10 coding system cannot distingui…
View article: Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study Open
Results from this large, real-world study of US patients with SCLC in the 3L setting and beyond highlight the poor treatment outcomes in advanced SCLC patients with existing therapies and underscore the dire need for new therapies for SCLC…
View article: Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer Open
View article: P2.17-01 Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer
P2.17-01 Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer Open
View article: Diversity and Representation Among United States Participants in Amgen Clinical Trials
Diversity and Representation Among United States Participants in Amgen Clinical Trials Open
View article: Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study
Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study Open
These results suggest that differential RTM could be reasonably addressed by propensity score models with summaries of historical laboratory values. This approach can be easily applied to any comparative effectiveness or safety study, thou…
View article: SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015
SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015 Open
Background: Over the last several years, the approval of new pharmacotherapies, changes to health plan formularies limiting treatment access, the emergence of new evidence related to medication safety and effectiveness, and updates to clin…
View article: The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data
The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data Open
Our study validated a claims-based algorithm for the identification of incident and recurrent fractures in administrative data. We used Centers for Medicare and Medicaid (CMS) claims from 2005 to 2014 linked to the Reasons for Geographic a…
View article: Risk of subsequent fracture after prior fracture among older women
Risk of subsequent fracture after prior fracture among older women Open
We observed a high and early risk of subsequent fracture following a broad array of initial fractures. Timely management with consideration of pharmacotherapy is warranted in older women following all fracture types evaluated.
View article: Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study Open
Persistence with denosumab for 24 months yields improvement in BMD among postmenopausal women with osteoporosis treated in routine clinical practice in the USA and Canada.
View article: Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions
Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions Open
The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (…
View article: Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women Open
In summary, reductions in fracture incidence over time were observed in cohorts of patients treated with osteoporosis therapies.
View article: Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting Open
Objective. Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD) to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, the risk of infection with concurrent use of denosumab, a …